Clinical Trials Logo

Filter by:
NCT ID: NCT03153111 Completed - Clinical trials for Heart Failure With Preserved Ejection Fraction

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

SERENADE
Start date: July 11, 2017
Phase: Phase 2
Study type: Interventional

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease. The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these patients.

NCT ID: NCT03151551 Completed - Psoriatic Arthritis Clinical Trials

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

SPIRIT-H2H
Start date: August 24, 2017
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

NCT ID: NCT03150589 Completed - Clinical trials for Age-Related Macular Degeneration

A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Start date: March 14, 2018
Phase: Phase 3
Study type: Interventional

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB11 compared to Lucentis® in subjects with neovascular AMD.

NCT ID: NCT03149445 Completed - Clinical trials for Confirmed Genetic Diagnosis of Prader-Willi Syndrome

Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)

2016-003694-18
Start date: March 30, 2017
Phase: Phase 2
Study type: Interventional

Two-centre, double-blind, placebo-controlled, randomized, and multiple-dose clinical study followed by two open label extension periods.

NCT ID: NCT03148795 Completed - Prostate Cancer Clinical Trials

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Start date: July 4, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

NCT ID: NCT03145441 Completed - Clinical trials for Cardiopulmonary Bypass

Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation

Start date: April 9, 2018
Phase: N/A
Study type: Interventional

There are several factors initiating cytokine storm and dysregulated systemic inflammatory response during cardiac transplantation. This may lead to serious perioperative complications: circulatory collapse, respiratory insufficiency, acute renal and liver failure, multi-organ dysfunction etc. On the other hand the high level of cytokines may play an important role in the development of graft rejection which is still a relevant problem in this patient group. There are some new data showing that the use of extracorporeal cytokine adsorber during long cardiopulmonary bypass time (>120min) may be beneficial to prevent SIRS (Systemic Inflammatory Response Syndrome) with decreasing the level of cytokines in patients undergoing elective cardiac surgery. However there is lack of data and studies regarding the effect of extracorporeal cytokine adsorption during cardiac transplantation. The aim of the study is to investigate the effect of extracorporeal cytokine adsorber built in the cardiopulmonary bypass circle during heart transplantation. The hypothesis is that removal of cytokines during heart transplantation prevents the development of extreme systemic inflammatory response, hemodynamic collapse dominated by vasoplegia, and contribute to reduce the incidence of severe perioperative complications and early graft rejection.

NCT ID: NCT03138655 Completed - Ulcerative Colitis Clinical Trials

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Start date: November 8, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.

NCT ID: NCT03137173 Completed - Clinical trials for Acute Bacterial Skin and Skin Structure Infections

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Start date: February 19, 2018
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind, active-controlled, parallel-group, multicenter study in adult hospitalized patients to establish the safety and efficacy of ceftobiprole medocaril compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

NCT ID: NCT03129100 Completed - Clinical trials for Axial Spondyloarthritis

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

Start date: May 9, 2017
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

NCT ID: NCT03126435 Completed - Clinical trials for Pancreatic Adenocarcinoma

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Start date: October 16, 2018
Phase: Phase 3
Study type: Interventional

The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic cancer after FOLFIRINOX failure.